Personalis/$PSNL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Ticker
$PSNL
Sector
Primary listing
Employees
229
Headquarters
Website
Personalis Metrics
BasicAdvanced
$756M
-
-$1.18
1.77
-
Price and volume
Market cap
$756M
Beta
1.77
52-week high
$8.95
52-week low
$2.83
Average daily volume
951K
Financial strength
Current ratio
6.095
Quick ratio
5.774
Long term debt to equity
17.93
Total debt to equity
22.671
Interest coverage (TTM)
-877.98%
Profitability
EBITDA (TTM)
-61.575
Gross margin (TTM)
31.45%
Net profit margin (TTM)
-113.70%
Operating margin (TTM)
-89.64%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-20.26%
Return on equity (TTM)
-60.26%
Valuation
Price to revenue (TTM)
8.228
Price to book
3.96
Price to tangible book (TTM)
3.96
Price to free cash flow (TTM)
-13.437
Free cash flow yield (TTM)
-7.44%
Free cash flow per share (TTM)
-0.635
Growth
Revenue change (TTM)
0.36%
Earnings per share change (TTM)
-27.15%
3-year revenue growth (CAGR)
1.68%
3-year earnings per share growth (CAGR)
-17.31%
What the Analysts think about Personalis
Analyst ratings (Buy, Hold, Sell) for Personalis stock.
Bulls say / Bears say
Personalis’ total revenue rose 6% year over year to $20.6 million in Q1 2025, exceeding Wall Street estimates of $17.4 million and reflecting growing market demand (GenomeWeb May 7, 2025).
Biopharma segment revenue grew 39% year over year to $13.6 million in Q1 2025, driven by strong adoption of the NeXT Personal platform in pharma tests and services (GenomeWeb May 7, 2025).
In Q2 2025, Personalis expanded its strategic collaboration with Tempus AI to include colorectal cancer, significantly enhancing its commercial reach and growth potential in a high-value indication (Business Wire Aug 5, 2025).
Personalis reported Q2 2025 revenue of $17.2 million, missing estimates of $20.11 million and marking a 24% year-on-year decline, underscoring weakening demand after losing key customer contracts (GuruFocus Aug 5, 2025).
Gross margin compressed by 8 percentage points to 27.6% in Q2 2025 from 35.6% a year earlier, driven by lower volumes and increased unreimbursed clinical test costs, straining profitability (MarketScreener Aug 5, 2025).
Revenue from enterprise sales, notably from Natera, collapsed by 71% in Q2 2025, creating a potential revenue cliff as contract revenues are not expected to continue beyond the year (Panabee Aug 6, 2025).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Personalis Financial Performance
Revenues and expenses
Personalis Earnings Performance
Company profitability
Personalis News
AllArticlesVideos
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 month ago
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
Business Wire1 month ago
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Personalis stock?
Personalis (PSNL) has a market cap of $756M as of October 17, 2025.
What is the P/E ratio for Personalis stock?
The price to earnings (P/E) ratio for Personalis (PSNL) stock is 0 as of October 17, 2025.
Does Personalis stock pay dividends?
No, Personalis (PSNL) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next Personalis dividend payment date?
Personalis (PSNL) stock does not pay dividends to its shareholders.
What is the beta indicator for Personalis?
Personalis (PSNL) has a beta rating of 1.77. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.